RESPIRATORY SYSTEM: ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A TEACHER’S COMPREHENSIVE GUIDE
Welcome, future pharmacists and healthcare professionals!
Respiratory system disorders are among the most common and debilitating conditions affecting millions of people worldwide. From a mild common cold to life-threatening conditions like asthma, COPD, pneumonia, and lung cancer, respiratory diseases impact the quality of life and can be fatal if not managed properly. As a pharmacy educator with years of experience teaching pharmacotherapeutics, I have observed that students often find respiratory diseases challenging due to their complex pathophysiology. Let me tell you: Understanding respiratory diseases is essential for every pharmacy professional.
In this comprehensive guide, I will walk you through the major respiratory diseases—asthma and Chronic Obstructive Pulmonary Disease (COPD). I will explain their types, etiology, pathogenesis, clinical manifestations, and both non-pharmacological and pharmacological management. By the end of this article, you will have a thorough understanding of these critical conditions. Let us begin our journey!
Dpharmguru’s exam insights:
Respiratory diseases are frequently tested in pharmacy exams. Remember: Asthma is a chronic inflammatory disease of the airways with reversible airflow obstruction. COPD is characterized by chronic obstruction of lung airflow that is not fully reversible. Pay special attention to the types of asthma (extrinsic vs intrinsic) and the difference between asthma and COPD—these are classic exam questions. Also, remember the pharmacological management of both conditions!
INTRODUCTION TO RESPIRATORY SYSTEM DISORDERS
The medical terminologies used to examine the several infections, allergies, and other diseases associated with the various respiratory organs, tissues, and specialized cells that form the human respiratory system are respiratory system disorders or respiratory diseases.
The upper respiratory tract, alveoli, bronchi, bronchioles, trachea, pleura, and pleural cavity form the respiratory system. A moderate respiratory illness like the common cold is compared to more serious and sometimes fatal respiratory illnesses including pneumonia, lung cancer, asthma, COPD, influenza, tuberculosis, etc.
ASTHMA
A chronic inflammatory disease of the airways in which variable periodic symptoms occur, along with airflow obstruction, and bronchial hyper-responsiveness, is termed as asthma. Obstruction of airways leads to reversible episodes of wheezing, breathlessness, chest tightness, and cough (worse at night and in early morning). These episodes which normalize either by their own or require to be treated, also increase the sensitivity of bronchi to various stimuli.
Types of Asthma
- Extrinsic Asthma: Initiated by a type I hypersensitivity (atopic) response to an extrinsic antigen. This type is allergic in nature.
- Intrinsic Asthma: Initiated by non-immune mechanisms, such as respiratory tract infections, exercise, aspirin, emotional upset, and exposure to bronchial irritants (cigarette smoke).
Etiology of Asthma
Genetic factors along with environmental exposure to inhaled allergens result in allergic reactions or irritate the airways. Following are the allergens of asthma:
- Allergens (house dust, mites in bedding, carpets and stuffed furniture, pollution, pollens and moulds, and pet dander)
- Respiratory infections
- Tobacco smoke
- Chemical irritants in the workplace
- Drugs (e.g., Aspirin, NSAIDs, β-blockers)
- Cold air, anger, fear, and physical exercise
Pathogenesis of Asthma
When the type 2 helper T (TH2) cells are activated, they produce cytokines responsible for most of the features of atopic asthma:
- Production of IgE by IL-4 and IL-13
- Activation of eosinophils by IL-5
- Production of mucus by IL-13
The sub-mucosal mast cells (otherwise coated with IgE) when exposed to allergen, release their granule contents, cytokines, and other mediators. Two types of reactions are produced:
- Early-phase or Immediate Reaction: Characterized by bronchoconstriction, increased mucus production, and vasodilation. Mast cell-derived mediators (histamine, prostaglandin D2, and leukotrienes) and reflex neural pathways cause bronchoconstriction.
- Late-phase Reaction: This is an inflammatory reaction. Mediators stimulate production of chemokines (such as eotaxin) by epithelial cells. Chemokines allow the involvement of Th2 cells, eosinophils, and other leukocytes. Frequent episodes of inflammation lead to airway remodelling—structural changes in the bronchial wall including hypertrophy of bronchial smooth muscles and mucus glands, increased vascularity, and excessive deposition of subepithelial collagen.
Clinical Manifestations of Asthma
- Coughing (worse at night)
- Wheezing (whistling sound produced in the respiratory airways during breathing)
- Breathlessness
- A feeling of tightness, pain, or pressure in chest
Different asthma attacks may have different symptoms ranging from mild to severe. Symptoms of asthma are not the same in each individual.
Non-Pharmacological Management of Asthma
- Help patient and family understand the disease and build self-esteem and fitness
- Instruct patient to avoid smoking
- Instruct patient to avoid identified cause (when possible)
- Control extrinsic factors that cause allergy (pets, moulds, and specific food stuffs), especially in children
- Instruct patient to avoid β-blockers, Aspirin, and NSAIDs
Pharmacological Management of Asthma
1) Long-Term Asthma Control Medications
- Inhaled Corticosteroids: Fluticasone, Budesonide, Flunisolide, Ciclesonide, Beclomethasone, Mometasone, Fluticasone furoate
- Leukotriene Modifiers: Montelukast, Zafirlukast, Zileuton
- Long-Acting β-Agonists: Salmeterol, Formoterol
- Combination Inhalers: Fluticasone-Salmeterol, Budesonide-Formoterol, Formoterol-Mometasone
- Theophylline: Bronchodilator taken as a daily pill
2) Quick-Relief (Rescue) Medications
- Short-Acting β-Agonists: Albuterol, Levalbuterol
- Ipratropium: Bronchodilator that rapidly relaxes airways
3) Allergy Medications
- Allergy Shots (Immunotherapy): Gradual decrease in immune system reaction to specific allergens
- Omalizumab: Injected every 2-4 weeks; alters the immune system
Dpharmguru’s exam insights:
Asthma management is frequently tested. Remember: Long-term control medications include inhaled corticosteroids and long-acting β-agonists. Quick-relief medications include short-acting β-agonists (Albuterol). A common exam question is: “What is the difference between asthma and COPD?” (Answer: Asthma has reversible airflow obstruction; COPD has irreversible airflow obstruction).
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Chronic Obstructive Pulmonary Disease (COPD) is also known as Chronic Obstructive Lung Disease (COLD), Chronic Obstructive Airway Disease (COAD), Chronic Airflow Limitation (CAL), and Chronic Obstructive Respiratory Disease (CORD).
It is characterized by inflamed lungs and obstruction in airflow (both to the lungs as well as from the lungs). Thus, a patient affected with this disease faces difficulty in breathing (shortness of breath) due to constriction (narrowing) of the airway. It is a progressive disease which worsens over time, in contrast to asthma wherein the obstruction to airflow is reversed.
According to WHO, a lung disease characterized by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible is termed COPD.
The American Thoracic Society (ATS) has defined COPD as “a disease state characterized by the presence of airflow limitation due to chronic bronchitis or emphysema; the airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible”.
Types of COPD
- Emphysema: The starting stage and common type of COPD in which air sacs of the lungs get damaged, enlarged, and finally burst. Patient experiences difficulty in expelling air due to the damaged air sacs. This leads to increased concentration of carbon dioxide and various symptoms of emphysema.
- Chronic Bronchitis: Refers to inflammation and irritation of the respiratory tract, resulting in formation of thick mucus. As time passes, this mucus blocks the respiratory tract and makes breathing difficult; when patient expels this mucus it is known as phlegm or sputum.
Etiology of COPD
- Environmental Factors: Polluted air, use of biomass fuel, long-term exposure to traffic-related air pollution
- Airway Hyper-Responsiveness: Non-specific airway hyper-reactivity, especially in people with smoking habits
- Genetic Factors: Family history of COPD, deficiency of AAT (Alpha-1-Antitrypsin)
- Earlier Infections: Tuberculosis, pneumonia, and other respiratory disorders
- Age: Elderly people are more susceptible to respiratory disorders
Pathogenesis of COPD
COPD symptoms occur due to chronic bronchitis and emphysema, which mostly arise from an exaggerated inflammatory reaction to cigarette smoke.
- Chronic Bronchitis: Results from hypertrophy of mucus-secreting epithelial glands of the larger airways—characterized by chronic cough and excessive sputum production
- Emphysema: Results from deterioration of the walls of air spaces within the bronchioles and alveoli—characterized by enlargement of these air spaces
These conditions variably contribute to COPD; thus indicating that some individuals will have only chronic bronchitis, some will have emphysema, and some will suffer from both.
Clinical Manifestations of COPD
- Shortness of breath, especially during physical activities
- Wheezing
- Chest tightness
- A chronic cough that produces clear, white, yellow, or greenish mucus (sputum)
- Respiratory infections on a regular basis
- Lack of energy
- Unintended weight loss (in later stages)
- Swollen ankles, foot, or leg
- Exacerbations (episodes in which symptoms worsen beyond normal day-to-day variance)
Non-Pharmacological Management of COPD
- Smoking Cessation: Patient should be advised to quit smoking
- Lung Therapies:
- Oxygen Therapy: Supplemental oxygen if blood concentration decreases
- Pulmonary Rehabilitation Program: Counseling, education, training, exercise, and nutrition advice
Pharmacological Management of COPD
- Bronchodilators: Relax bronchial muscles to make breathing easier
- Long-Acting: Arformoterol, Indacaterol, Aclidinium, Tiotropium, Salmeterol, Formoterol
- Short-Acting: Levalbuterol, Ipratropium, Albuterol
- Inhaled Steroids: Budesonide, Fluticasone—reduce inflammation
- Combination Inhalers: Fluticasone + Salmeterol; Budesonide + Formoterol
- Oral Steroids: Short-term courses (mostly for 5 days) for moderate to severe acute exacerbation
- Phosphodiesterase-4 Inhibitors: Roflumilast—for severe COPD and chronic bronchitis
- Theophylline: Smooth muscle relaxant; prevents exacerbations and improves breathing
- Antibiotics: Azithromycin, Levofloxacin, Cefixime—for respiratory infections that aggravate COPD
Dpharmguru’s exam insights:
COPD management is frequently tested. Remember: Bronchodilators are the mainstay of COPD treatment. Long-acting bronchodilators (Tiotropium, Salmeterol) are preferred for maintenance therapy. Inhaled corticosteroids are used for frequent exacerbations. A common exam question is: “What is the difference between emphysema and chronic bronchitis?” (Answer: Emphysema involves damaged air sacs; chronic bronchitis involves inflammation and mucus production).
COMPARISON: ASTHMA VS COPD
| Feature | Asthma | COPD |
|---|---|---|
| Airflow Obstruction | Reversible | Not fully reversible |
| Onset | Often in childhood | Usually in middle age or later |
| Cause | Allergic, genetic, environmental | Smoking, environmental, genetic |
| Symptoms | Variable, episodic | Progressive, persistent |
| Inflammation | Eosinophilic | Neutrophilic |
| Response to Corticosteroids | Excellent | Moderate to poor |
FREQUENTLY ASKED QUESTIONS (FAQs)
1. What is the difference between asthma and COPD?
Asthma is characterized by reversible airflow obstruction and is often allergic in nature. COPD is characterized by irreversible airflow obstruction and is usually caused by smoking or environmental factors.
2. What is the difference between extrinsic and intrinsic asthma?
Extrinsic asthma is initiated by a type I hypersensitivity (atopic) response to an extrinsic antigen (allergic). Intrinsic asthma is initiated by non-immune mechanisms such as respiratory infections, exercise, aspirin, emotional upset, and exposure to bronchial irritants.
3. What is the difference between emphysema and chronic bronchitis?
Emphysema involves damaged air sacs that become enlarged and burst, making it difficult to expel air. Chronic bronchitis involves inflammation and irritation of the respiratory tract, resulting in formation of thick mucus that blocks the respiratory tract.
4. What are the long-term control medications for asthma?
Long-term control medications include inhaled corticosteroids (Fluticasone, Budesonide), leukotriene modifiers (Montelukast), long-acting β-agonists (Salmeterol, Formoterol), combination inhalers, and Theophylline.
5. What are the quick-relief medications for asthma?
Quick-relief medications include short-acting β-agonists (Albuterol, Levalbuterol) and Ipratropium.
6. What is the most common cause of COPD?
The most common cause of COPD is cigarette smoking, which leads to an exaggerated inflammatory reaction in the lungs. Other causes include environmental pollution, genetic factors, and respiratory infections.
SUMMARY
Respiratory diseases are among the most common and serious conditions affecting global health. This guide covered the major respiratory diseases:
- Asthma: Chronic inflammatory disease with reversible airflow obstruction. Managed with inhaled corticosteroids, long-acting β-agonists, leukotriene modifiers, and quick-relief bronchodilators
- COPD: Chronic progressive disease with irreversible airflow obstruction. Managed with bronchodilators, inhaled steroids, phosphodiesterase-4 inhibitors, and antibiotics
As I always tell my students: “Respiratory diseases are preventable and manageable. Understanding the pathophysiology and pharmacology of these conditions is essential for improving patient outcomes and quality of life.”
REFERENCES AND FURTHER READING
- Pharmacy Council of India (PCI). (2022). Pharmacotherapeutics Syllabus. New Delhi: PCI.
- Rang, H. P., & Dale, M. M. (2021). Rang & Dale’s Pharmacology (9th ed.). Elsevier.
- Goodman, L. S., & Gilman, A. (2018). Goodman & Gilman’s The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill.
- Katzung, B. G. (2021). Basic and Clinical Pharmacology (15th ed.). McGraw-Hill.
- Global Initiative for Asthma (GINA). (2023). Global Strategy for Asthma Management and Prevention.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). Global Strategy for the Diagnosis, Management, and Prevention of COPD.
- World Health Organization (WHO). (2022). Respiratory Diseases. Retrieved from https://www.who.int.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for medical concerns. Pharmaceutical regulations and guidelines may vary by region—always refer to your local regulatory authorities for specific requirements.
written by:
Dr. N. Sujith Kumar
For More Study Materials, Visit: www.dpharmguru.com
